Development, optimization and implementation of retro-orbital fibroblast cultures in our laboratory.
ID
Source
Brief title
Condition
- Thyroid gland disorders
- Ocular infections, irritations and inflammations
- Autoimmune disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Production of IL-16 by orbital fibroblast in culture after stimulation with
patient IgG.
Secondary outcome
Production of RANTES, hyaluronan and the proliferation level of orbital
fibroblasts in culture after stimulation with patient IgG.
Background summary
In the present model of immune pathogenesis of Graves* ophtalmopathy, a
concerted action of various immune cells and antibodies is conjectured to cause
this thyroid eye disease. In vitro studies may help to understand these
processes more thoroughly.
Study objective
Development, optimization and implementation of retro-orbital fibroblast
cultures in our laboratory.
Study design
Laboratory study of immunological processes involving the retro-orbital
fibroblast.
Study burden and risks
Participants of this study do not benefit from the results of this study. Risks
are negligible.
Schiedamse Vest 180
3011 BH Rotterdam
NL
Schiedamse Vest 180
3011 BH Rotterdam
NL
Listed location countries
Age
Inclusion criteria
General inclusion criteria:
- age >= 18 years
- written informed consent;Graves* patients:
- hyperthyroid
- raised free thyroxin (fT4) level
- decreased TSH level
- diffuse non-nodular appearance of thyroid on palpation, scan or ultrasonography
- positivity for TSH-receptor antibodies (Brahms Diagnostics, Berlin, Germany);Contrast AT patients:
- clinically hypothyroid
- lowered serum fT4 level
- raised TSH level
- positive for TPO antibodies
- negative for TSH-receptor antibodies (Brahms Diagnostics, Berlin, Germany);Healthy individuals:
- self-proclaimed good health
- free of any obvious medical illness for at least two weeks prior to the blood withdrawal, including acute infections and allergic reactions
- no medication (apart from anti-conceptive hormonal therapy)
Exclusion criteria
The exclusion criteria for all subjects in the study are: any immune disorder other than thyroid autoimmunity, serious other medical illness, recent infections (last 2 weeks), fever, pregnancy/postpartum for 6 months, obvious vascular complications.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL16991.078.07 |